- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Amphetamine Extended Release Suspension [Dyanavel]
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 4 Years to 5 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Maitland, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–2
of 2
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- amphetamine extended-release oral suspension, 2.5 mg/mL, Placebo extended-release oral suspension
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada